Ready 8-Ks
3
Latest filing
June 17, 2026, 8:03 AM ET
Top materiality
0.55
Event mix
other_material ×2 · earnings ×1
Sentiment
1 pos · 0 neg · 2 neu
Recent 8-K filings for AVLN
Highest-materiality recent filing
Avalyn completes Phase 2b MIST trial enrollment of 375 patients for inhaled pirfenidone in PPF; topline data H2 2027
- Completed target enrollment of 375 patients in Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis (PPF).
- Trial is randomized, double-blind, placebo-controlled, evaluating two doses (50 mg and 100 mg BID) vs placebo; primary endpoint is change in FVC at 52 weeks.
No notable filings for this issuer yet. See all filings.
Materiality & sentiment trend
Max materiality 0.55 · Median 0.50 · Most common event other_material